In the BioHarmony Drug Report Database

"Preview" Icon

Saxagliptin

Onglyza (saxagliptin) is a small molecule pharmaceutical. Saxagliptin was first approved as Onglyza on 2009-07-31. It is used to treat type 2 diabetes mellitus in the USA. It has been approved in Europe to treat type 2 diabetes mellitus. The pharmaceutical is active against dipeptidyl peptidase 4. Onglyza’s patents are valid until 2028-11-30 (FDA).

 

Trade Name

 

Onglyza
 

Common Name

 

saxagliptin
 

ChEMBL ID

 

CHEMBL2103745
 

Indication

 

type 2 diabetes mellitus
 

Drug Class

 

Dipeptidyl aminopeptidase-IV inhibitors

Image (chem structure or protein)

Saxagliptin structure rendering